![Shelia Violette](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Shelia Violette
Geen lopende functies
Vermogen: 2 M $ op 31-08-2026
Profiel
Shelia Violette is the founder of Q32 Bio, Inc., founded in 2017, serving as Chief Scientific Officer & President-Research since 2024.
Current jobs include Advisor at Atlas Venture Advisors, Inc. since 2021 and Chief Scientific Officer at Q32 Bio Operations, Inc. since 2017.
Former jobs include Director at CytImmune Sciences, Inc. from 2021 to 2023, Principal at Repligen Corp., Principal at ARIAD Pharmaceuticals, Inc., Vice President-Research at Biogen, Inc., and Vice President-Research at Stromedix, Inc. Education includes a doctorate from Yale University conferred in 1989.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
0,55% | 25-08-2026 | 164.048 ( 0,55% ) | 2 M $ | 31-08-2026 |
Actieve functies van Shelia Violette
| Bedrijven | Functie | Begin |
|---|---|---|
Q32 Bio, Inc.
 Q32 Bio, Inc. BiotechnologyHealth Technology Develops immunomodulatory therapies with protein based molecules using a platform | Hoofd Techniek/Wetenschap/O&O | 01-01-2017 |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors invests in companies located in the United States. The firm focuses on life sciences and biotech sectors. It provides financing for early stage capital requirements. | Consultant / Adviseur | 01-01-2021 |
Eerdere bekende functies van Shelia Violette
| Bedrijven | Functie | Einde |
|---|---|---|
CytImmune Sciences, Inc.
 CytImmune Sciences, Inc. BiotechnologyHealth Technology Develops and manufactures cytokine immunoassay kits | Directeur/Bestuurslid | 01-06-2023 |
| BIOGEN INC. | Hoofd Techniek/Wetenschap/O&O | - |
| ARIAD PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| REPLIGEN CORPORATION | Corporate Officer/Principal | - |
Stromedix, Inc.
 Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Develops novel drugs to treat fibrosis and fibrotic organ failure | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Shelia Violette
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
96
Eerstegraads connecties
8
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 8 |
|---|---|
Repligen Corp.
 Repligen Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures biologic drugs | Health Technology |
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes small-molecule drugs for the treatment of cancer | Health Technology |
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
CytImmune Sciences, Inc.
CytImmune Sciences, Inc. BiotechnologyHealth Technology Develops and manufactures cytokine immunoassay kits | Health Technology |
Stromedix, Inc.
Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Develops novel drugs to treat fibrosis and fibrotic organ failure | Health Technology |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors invests in companies located in the United States. The firm focuses on life sciences and biotech sectors. It provides financing for early stage capital requirements. | Finance |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Q32 Bio, Inc.
Q32 Bio, Inc. BiotechnologyHealth Technology Develops immunomodulatory therapies with protein based molecules using a platform | Health Technology |
